Commit Biologics raises USD 60 million seed round
Commit Biologics has closed a USD 60 million (EUR 54 million) seed financing to take its first complement-powered immune engager, COM002, toward the clinic.
Ackermans & van Haaren led the round, with AbbVie Ventures and M Ventures joining as new investors alongside existing backers Bioqube Ventures, Korys and Novo Holdings. Representatives of the three new investors join the board.
The money will fund IND-enabling work and an IND filing for COM002, move a second program into IND-enabling development, and expand the company’s BiCE (Bispecific Complement Engager) pipeline. COM002 is designed to deplete targeted immune cells by recruiting the complement system rather than T cells. It will first be developed in relapsed or refractory non-Hodgkin lymphoma, with plans to expand into autoimmune disease. Dosing of the first patient is expected in early 2028.
Commit is a spin-out from Aarhus University and has sites in Copenhagen and Aarhus.
Ackermans & van Haaren is proud to lead the financing “to realize the full potential of the BiCE platform,” says Lenny Van Steenhuyse, investment manager at the firm.
Updated: November 18, 2026, 08:37 am
Published: November 17, 2026
